Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05976828 · ClinicalTrials.gov registry record · Phase 1
IBRX-042 In Participants With HPV-Associated Tumors
A Phase 1 study of HPV-Related Carcinoma, sponsored by ImmunityBio.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT05976828 is a Phase 1 study of HPV-Related Carcinoma that is active but no longer recruiting, run by ImmunityBio. The registered enrollment target is 12 participants, below the 154-participant average among 10 other HPV-Related Carcinoma trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05976828, a Phase 1 study of HPV-Related Carcinoma, is active but no longer recruiting, sponsored by ImmunityBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are: * What is the maximum tolerated dose of IBRX-042? * How well does the study drug treat cancer? * What effects the study drug may have on the human body and cancer? Participants will receive IBRX-042 at one of three dose levels every 3 weeks for a total of 3 injections. Participants will undergo tests, exams, and procedures that are part of standard of care and for study purposes. IBRX-042 will be administered by injection every 3 weeks for a total of 3 injections.
Conditions Studied
Interventions
- DRUG IBRX-042
Study Locations (3)
Texas
- Texas Oncology Austin Central - Austin
- The University of Texas - MD Anderson Cancer Center - Houston
California
- Chan Soon-Shiong Institute for Medicine (CSSIFM) - El Segundo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-06-14 |
| Est. Completion | 2033-08-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05976828
The ClinicalTrials.gov registry entry for NCT05976828 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 10 other HPV-Related Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HPV-Related Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which IBRX-042 is the first listed.
NCT05976828 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, California.
Frequently Asked Questions
What is clinical trial NCT05976828 about?
NCT05976828 is a clinical study titled "IBRX-042 In Participants With HPV-Associated Tumors". The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are: * What is ...
What is the current status of trial NCT05976828?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-06-14. Estimated completion is 2033-08-14.
What conditions does trial NCT05976828 study?
This clinical trial studies the following conditions: HPV-Related Carcinoma.
What interventions are being tested in trial NCT05976828?
The interventions under investigation include: IBRX-042 (DRUG).
Who is sponsoring clinical trial NCT05976828?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05976828 being conducted?
This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV-Related Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
RECRUITING · Phase 1
-
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
RECRUITING
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.